Many use mice for contemporary cardiovascular research, as we should, given the power of the genetic and other tools developed to permit rigorous mechanistic experimentation in this species.
"These experimental results in mice suggest that X is a promising novel target for the treatment of human cardiovascular disease" (A paraphrase of the concluding sentence of many contemporary cardiovascular research papers) Most use mice. We must use mice for much contemporary cardiovascular
experimentation. Yet, we must not succumb to "group think" about the ready translatability of our experimental results to the clinic. Although many millennia of evolution separate them from humans 1 , mice provide incredibly valuable tools for biomedical investigation. In particular, the availability of inbred strains and the development of ever more powerful techniques for sophisticated genetic manipulation allow "reductionist" experiments of increasing complexity, sophistication, and rigor. On the other hand, the primacy of mice as experimental animals for cardiovascular research over the last 25 years may have fostered a tendency to minimize some of the limitations of modified mice as "models" for human diseases. This commentary highlights some of the issues to which we as a community might pay more heed in interpreting and extrapolating to humans the results of our mouse experiments. I do not denigrate the use of these powerful approaches to experimental work. Rather, this essay aims to raise some of the issues that require consideration and rigorous thinking regarding the relationship of our laboratory approaches to clinical cardiovascular disease. I consider serially a number of such potential limitations.
Congenic Strains -An Enabling Strength, but also a Potential Weakness
We possess a repertoire of over 100 exceedingly well-characterized congenic strains of These considerations reflect a variant of the "hygiene hypothesis" that microbial challenges to the immune system in more sanitary environments affect the development of the immune system. 5 6 Indeed, wild rats and wild mice exhibit higher IgG and IgE concentrations in serum than rodents in the laboratory. The immune system of wild-caught rats contrasts considerably with those of laboratory animals in relation to T cell characteristics as well. 7 8 Some have invoked the "hygiene hypothesis" to explain increases in allergic diseases in postindustrial societies. From our experimental perspective we need to remain mindful that the immune system of our favorite laboratory mice may vary considerably from field mice and from human populations exposed to a broader environment of microbes both pathogenic and commensal. The lack of constant challenge by a diversity of microorganisms and a more monotonous microbiome distorts the immune response in our laboratory mice. Moreover, the 
Mice Have a More Categorical Immune System Than Humans
Another challenge to the ready translatability of experiments the immune system in mice versus humans relates to the apparently less strict demarcation between functional subtypes of both innate and adaptive immune cells in humans than mice. 9 For example, an enormous literature has focused on Th1 versus Th2, regulatory T cell (T reg ) functions, and differences between B1 and B2 lymphocytes in experimental preparations. In the realm of innate immunity, the study of "M1" versus "M2" macrophages has become a common refrain. 10 Yet, considerable evidence suggests that the strict categorization of these functional subsets of both adaptive and innate immune cells in humans has more diffuse borders and perhaps greater instability than evident in the mouse. Immunologic researchers have called attention to the differences in functional markers and stability of T regs in mice versus humans. 11 12 Moreover, the markers commonly used for "phenotyping" macrophages in mice render less clear results in humans. Interpretation of the results of manipulations of the mouse immune system for human disease should take these disparities into account more frequently.
Are Our "Models" Really Such?
We often engage in laboratory perturbations in mice with various genetic modifications to delineate the roles of specific mediators in human disease. Such an approach offers enormous
value. Yet our manipulations, while convenient and often reproducible, may stray substantially from replicating the human situation. Likewise, in studies of myocardial biology we perform transverse aortic constriction ("TAC") in mice that often have previously normal hearts, in an attempt to "model" disease of human hearts that often have chronic rather than acute pressure overload that yields an abnormal heart before experiencing critical outflow obstruction. Likewise, our common "ischemia/reperfusion" preparations in the mouse myocardium start with a normal vasculature and myocardium rather than one diffusely affected by atherosclerosis and previous ischemic insults. Is it thus surprising that few if any of the multitudinous manipulations that have improved the outcome of experimental ischemia/reperfusion injury in mice and other animals have borne fruit in the clinic?
Mouse Experiments Usually Fail to Account for Comorbidities Common in Our Human Patients
The foregoing section highlighted distinctions between the normal substrate for intervention, both vascular and myocardial, in mice versus the human situation usually affected by chronic diseases of those organs. Beyond the cardiovascular system, our patients usually present with comorbidities that interlace inextricably with their cardiovascular disease. Common concomitant conditions include renal dysfunction, diabetes mellitus, obesity, tobacco abuse, periodontal disease, and pulmonary disease. These comorbidities inevitably influence the expression of cardiovascular disease. We appreciate increasingly the crosstalk between acute and chronic inflammatory activation remote to the myocardium or atheroma and "echoes" within the cardiovascular system. 14 15 16 Our well-defined and reproducible mouse experiments again fail to replicate the complexity of clinical cardiovascular disease, whose course often depends upon concomitant comorbidities.
The Time Scales of Laboratory Investigations and Human Disease Vary

Considerably (Funding Cycle versus Life Cycle)
Laboratories depend on funding cycles of a few years. Graduate students and postdoctoral fellows in common with principal investigators need to finish projects in a timely fashion to permit publications that allow them to advance to the next echelon of their professional careers or obtain the next limited cycle of grant funding to support their research.
These constraints cause us to eschew the long-term experiment in favor of short-term manipulations that can generate data rapidly and meet the short-term goals imposed on us by professional ladders and funding organizations. Hippocrates famously stated, "The art is long, life is short… experiment difficult…" He was doubtless correct for his era, and his assessment of the difficulty of experiment endures. Yet the sage had no conception that by making inroads in communicable diseases and other advances both societal and medical, that the human lifespan would become a lot longer in the 21 st century than in classical antiquity. Cardiology practice continues to shift towards an accumulation of the aged. As our experiments remain short, we adopt "models" of disease that do not reflect aging of the cardiovascular system.
Atherosclerotic mice commonly used in the laboratory typically have degrees of genetically-and/or dietarily-determined hyperlipidemia that caricature rather than mimic the human conditions. Such acceleration produces atherosclerotic lesions in mice in weeks not in
years. Yet, we blithely expect the lesions so produced to represent the ravages of a disease that plays out over decades in humans. In our haste to complete the next manuscript, to finish the thesis, and to compete for grant funding, we tend to sweep under the rug the enormous differences in time scale and the intensity of interventions between clinical and experimental disease in our cardiovascular experimentation.
Human Studies Have Limitations Too
The foregoing cautionary statements regarding mouse studies raise some similar limitations inherent in many clinical trials. As the interpretation of animal experiments requires caution, so too does the design and extrapolation to broader practice of clinical investigations. investigators alike to conclude a study, albeit for distinct reasons. We often encounter disappointment when extrapolating the results of smaller phase 2 studies, particularly those that employ surrogate endpoints rather than clinical events. We must bear these limitations in mind when evaluating human studies, as I urge for experimental work above.
Conclusions and Implications
These and doubtless other important considerations highlight the challenges of interpreting our investigations conducted in mice. Should we therefore abandon such experiments? That conclusion comprises a reductio ad absurdum. We should and must use mouse experiments to propel our field forward. Nonetheless, we must not neglect the gaps that yawn between these convenient and powerful animal preparations and human disease. Our laboratory group tries to practice the discipline of using the term "model" cautiously.
We favor the stance that animal experiments provide us with a rich opportunity to test defined hypotheses regarding pathophysiologic mechanisms under tightly controlled circumstances. This approach applies not only to mice, but also to experiments performed in other species: rats, rabbits, fish, and worms alike. 17 I challenge trainees and colleagues with the assertion that attempts to "model" a human disease in mice virtually guarantee failure. I prefer the nostalgic term "preparation" as a more humble and perhaps realistic replacement for the word "model."
Ernest Henry Starling, a pioneer in cardiovascular physiology, realized that the "heart-lung preparation" that he developed at the dawn of contemporary cardiovascular physiology was not a model of human disease but a tool to use to gain pathophysiologic insight that provides the foundation and daily bread of contemporary hemodynamics and cardiovascular
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Peter Libby, MD 13 pathophysiology. 18 If the term "preparation" sufficed for Starling, perhaps it could serve us well as well.
Ultimately, cardiovascular science will continue its impressive advance by combining the rigor and control of laboratory experimentation with the much muddier reality of human patients and populations: the delight and challenge we encounter in daily practice. To achieve this end, we must continue to train physician-investigators, to encourage dialogue between laboratory scientists and clinical investigators, and to apply a dose of humility and introspection to the implications of our experimental work for human disease. 
Supplementary Figure Legend
This photograph shows the offerings of sake at Otoyo Shrine.
Sources of Funding
None.
Conflicts of Interest
